[68Ga]Ga-FAPI-04 PET/MR显像策略在胃印戒细胞癌Krukenberg瘤管理中的应用:克服[68Ga]Ga-FAPI-04 PET在Krukenberg瘤中的局限
回顾性分析12例胃印戒细胞癌患者的23个Krukenberg瘤,比较[68Ga]Ga-FAPI-04与[18F]FDG PET对原发灶、淋巴结及腹膜转移的检出能力。[68Ga]Ga-FAPI-04对原发灶(100% vs 18.2%,p=0.002)、淋巴结(90.9% vs 54.5%,p=0.046)和腹膜转移(100% vs 41.7%,p=0.008)的检出率优于[18F]FDG,但两者对Krukenberg瘤识别价值均有限。[68Ga]Ga-FAPI-04 PET/MR策略将Krukenberg瘤检出率提高至87%(20/23),加入DWI后进一步提高至100%(vs 87.5%,p=0.083),并使12例患者的TNM分期或治疗管理发生改变。
要点
- [68Ga]Ga-FAPI-04 PET对胃印戒细胞癌原发灶、淋巴结和腹膜转移的检出率优于[18F]FDG PET。
- 两种示踪剂对Krukenberg瘤识别价值均有限,[68Ga]Ga-FAPI-04 PET假阴性率100%,[18F]FDG PET检出率仅8.7%。
- [68Ga]Ga-FAPI-04 PET/MR策略使Krukenberg瘤检出率达87%,加DWI后达100%,并改变12例分期或治疗管理。
核心结论
- [68Ga]Ga-FAPI-04 PET在检测胃印戒细胞癌原发灶和多数卵巢外转移方面优于[18F]FDG PET,但两种示踪剂对Krukenberg瘤的识别价值均有限([68Ga]Ga-FAPI-04 PET假阴性率100%,[18F]FDG PET检出率8.7%)。
- 作者认为应应用盆腔MRI以弥补[68Ga]Ga-FAPI-04 PET识别Krukenberg瘤的局限性。
- [68Ga]Ga-FAPI-04 PET/MR显像策略有潜力影响伴Krukenberg瘤的胃印戒细胞癌患者的治疗决策。
研究设计与样本
- 回顾性分析12例胃印戒细胞癌患者的23个Krukenberg瘤(8例同时性、4例异时性),均行[68Ga]Ga-FAPI-04盆腔PET/MR及全身[68Ga]Ga-FAPI-04和[18F]FDG PET显像。
- 采用Wilcoxon符号秩检验或配对t检验比较两种示踪剂摄取,McNemar检验比较病灶检出率,双侧P<0.05为差异有统计学意义。
- 采用免疫组化分析Krukenberg瘤中成纤维细胞激活蛋白(FAP)表达。
主要发现
- [68Ga]Ga-FAPI-04 PET对胃印戒细胞癌原发灶检出率为100%(11/11),[18F]FDG PET为18.2%(2/11),p=0.002。
- [68Ga]Ga-FAPI-04 PET对受累淋巴结检出率为90.9%(10/11),[18F]FDG PET为54.5%(6/11),p=0.046。
- [68Ga]Ga-FAPI-04 PET对腹膜转移检出率为100%(12/12),[18F]FDG PET为41.7%(5/12),p=0.008,且[68Ga]Ga-FAPI-04 SUVmax和TBR均更高(all p<0.005)。
- [68Ga]Ga-FAPI-04 PET识别Krukenberg瘤的假阴性率为100%,[18F]FDG PET检出率为8.7%。
- 免疫组化显示肿瘤性印戒细胞和卵巢间质中FAP表达阴性或轻微;[68Ga]Ga-FAPI-04 PET/MR策略使Krukenberg瘤检出率达87%(20/23),加DWI后由87.5%提高至100%(p=0.083),并使12例患者的TNM分期升级或治疗管理改变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare performance of whole-body [68Ga]Ga-FAPI-04 and [18F]FDG PET imaging in the detection of Krukenberg tumors (KTs), primary site and extra-ovarian metastases of gastric signet-ring-cell carcinoma (GSRCC), and evaluate the value of [68Ga]Ga-FAPI-04 PET/MR imaging strategy and its potential impact on the management of KTs from GSRCC. METHODS: Twelve patients with twenty-three KTs from GSRCC, who underwent both [68Ga]Ga-FAPI-04 pelvic PET/MR and whole-body [68Ga]Ga-FAPI-04 and [18F]FDG PET imaging were retrospectively analyzed. [68Ga]Ga-FAPI-04 and [18F]FDG uptakes were compared by using Wilcoxon signed-rank test or paired t test. McNemar's test was used to compare lesion detectability between two modalities. Two-tailed P<0.05 was considered statistically significant. Immunohistochemistry staining was utilized to analyze the fibroblast activation protein (FAP) expression in KTs. RESULTS: A total of 12 patients with 23 KTs from GSRCC (8 synchronous and 4 metachronous) were evaluated. [68Ga]Ga-FAPI-04 was superior to [18F]FDG PET in detecting primary sites of GSRCC (100% [11/11] vs. 18.2% [2/11], p = 0.002), involved lymph nodes (90.9% [10/11] vs. 54.5% [6/11], p = 0.046) and peritoneal metastases (100% [12/12] vs. 41.7% [5/12], p = 0.008), with higher SUVmax and TBR (all p < 0.005). Both tracers had limited value in identifying KTs, with 100% false negative rate on [68Ga]Ga-FAPI-04 PET and a low detection rate of 8.7% on [18F]FDG PET. Fap immunohistochemistry showed negative or slight FAP expression in neoplastic signet ring cells and ovarian stroma. [68Ga]Ga-FAPI-04 PET/MR imaging strategy greatly improved the detection rate of Krukenberg tumors (87%, 20/23). After adding diffusion-weighted imaging (DWI), the detection rate was further improved (87.5% vs. 100%, p = 0.083). [68Ga]Ga-FAPI-04 PET/MR imaging strategy either upgraded TNM staging or changed treatment management in twelve patients. CONCLUSIONS: [68Ga]Ga-FAPI-04 PET outperformed [18F]FDG PET in detecting primary site and most extra-ovarian metastases of GSRCC, but both tracers had limited value in identifying Krukenberg tumors. Pelvis MRI should be applied to compensate the limitation of [68Ga]Ga-FAPI-04 PET imaging to identify Krukenberg tumours. The [68Ga]Ga-FAPI-04 PET/MR imaging strategy has the potential to impact treatment decisions for GSRCC patients with KTs.
引用
- Wang T, Huang G, Zhao H, et al. [68Ga]Ga-FAPI-04 PET/MR imaging strategy in management of Krukenberg tumors (KTs) from gastric signet-ring-cell carcinoma: to overcome limitation of [68Ga]Ga-FAPI-04 PET imaging in KTs. Eur J Nucl Med Mol Imaging. 2024. PMID: 38767660. doi:10.1007/s00259-024-06761-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。